LU91585I2 - Degarelix, éventuellement un sel pharmaceutiquement acceptable, tel que l'acétate (FIRMAGON) - Google Patents

Degarelix, éventuellement un sel pharmaceutiquement acceptable, tel que l'acétate (FIRMAGON)

Info

Publication number
LU91585I2
LU91585I2 LU91585C LU91585C LU91585I2 LU 91585 I2 LU91585 I2 LU 91585I2 LU 91585 C LU91585 C LU 91585C LU 91585 C LU91585 C LU 91585C LU 91585 I2 LU91585 I2 LU 91585I2
Authority
LU
Luxembourg
Prior art keywords
firmagon
degarelix
acetate
optionally
pharmaceutically acceptable
Prior art date
Application number
LU91585C
Other languages
English (en)
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25273352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91585(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of LU91585I2 publication Critical patent/LU91585I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/11—Gonadotropin; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
LU91585C 1997-04-11 2009-07-17 Degarelix, éventuellement un sel pharmaceutiquement acceptable, tel que l'acétate (FIRMAGON) LU91585I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/837,042 US5925730A (en) 1997-04-11 1997-04-11 GnRH antagonists
PCT/US1998/007438 WO1998046634A1 (fr) 1997-04-11 1998-04-13 ANTAGONISTES DE GnRH MODIFIES AUX POSITIONS 5 ET 6

Publications (1)

Publication Number Publication Date
LU91585I2 true LU91585I2 (fr) 2009-09-17

Family

ID=25273352

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91585C LU91585I2 (fr) 1997-04-11 2009-07-17 Degarelix, éventuellement un sel pharmaceutiquement acceptable, tel que l'acétate (FIRMAGON)

Country Status (37)

Country Link
US (2) US5925730A (fr)
EP (1) EP1003774B1 (fr)
JP (2) JP4249806B2 (fr)
KR (1) KR100519421B1 (fr)
CN (1) CN1230442C (fr)
AR (1) AR011217A1 (fr)
AT (1) ATE319736T1 (fr)
AU (1) AU728642B2 (fr)
BR (1) BR9808523B1 (fr)
CA (1) CA2286190C (fr)
CY (2) CY1108063T1 (fr)
CZ (1) CZ299097B6 (fr)
DE (2) DE69833751T2 (fr)
DK (1) DK1003774T3 (fr)
EE (1) EE03974B1 (fr)
ES (1) ES2260833T3 (fr)
FR (1) FR09C0028I2 (fr)
HK (1) HK1025104A1 (fr)
HR (1) HRP980197B1 (fr)
HU (1) HU224836B1 (fr)
IL (1) IL132303A0 (fr)
LU (1) LU91585I2 (fr)
MY (1) MY114811A (fr)
NL (1) NL300395I2 (fr)
NO (2) NO324991B1 (fr)
NZ (1) NZ500142A (fr)
PL (1) PL194509B1 (fr)
PT (1) PT1003774E (fr)
RU (1) RU2199549C2 (fr)
SI (1) SI1003774T1 (fr)
SK (1) SK285381B6 (fr)
TR (1) TR199902956T2 (fr)
TW (1) TW505658B (fr)
UA (1) UA58547C2 (fr)
UY (1) UY24958A1 (fr)
WO (1) WO1998046634A1 (fr)
ZA (1) ZA983062B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
WO1999026964A1 (fr) * 1997-11-20 1999-06-03 Ortho-Mcneil Pharmaceutical, Inc. PROCEDE EN PHASE LIQUIDE POUR L'ELABORATION DE PEPTIDES GnRH
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
IL147138A0 (en) * 2001-12-17 2002-08-14 Yeda Res & Dev Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
EP2322197A2 (fr) 2003-11-10 2011-05-18 Reprise Biopharmaceutics, LLC Compositions pharmaceutiques comportant de la desmopressine faiblement dosee
DE20321887U1 (de) 2003-11-10 2012-01-20 Allergan, Inc. Arzneimittel umfassend niedrige Dosierungen von Desmopressin
CN101037472B (zh) * 2006-03-14 2013-03-27 中国人民解放军军事医学科学院毒物药物研究所 具有低组胺释放作用的促黄体生成素释放激素拮抗剂
US7704977B2 (en) * 2006-04-07 2010-04-27 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
TWI442932B (zh) 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
JP2011519928A (ja) * 2008-05-07 2011-07-14 メリオン・リサーチ・Ｉｉｉ・リミテッド ペプチドの組成物及びその調製方法
CA2751854A1 (fr) * 2009-02-25 2010-09-02 Merrion Research Iii Limited Composition contenant un bisphosphonate et administration d'un medicament a base de bisphosphonate
SG175744A1 (en) 2009-04-24 2011-12-29 Polypeptide Laboratories As Method for the manufacture of degarelix
EP2424503B1 (fr) * 2009-05-01 2017-07-05 Ferring BV Composition pour le traitement du cancer de la prostate
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
WO2011066386A1 (fr) 2009-11-25 2011-06-03 Novetide, Ltd. Procédé de production de degarelix
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
EP2447276A1 (fr) 2010-10-27 2012-05-02 Ferring B.V. Procédé pour la fabrication du degarelix et de ses intermédiaires
PL2632934T3 (pl) 2010-10-27 2017-06-30 Ferring B.V. Sposób wytwarzania degareliksu i jego związków pośrednich
AU2011348220B2 (en) 2010-12-22 2017-09-07 The Salk Institute For Biological Studies Cyclic CRF antagonist peptides
AU2012204213A1 (en) 2011-01-07 2013-06-13 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
WO2013104745A1 (fr) 2012-01-13 2013-07-18 Ferring Bv Composition pharmaceutique
AR092840A1 (es) 2012-06-01 2015-05-06 Ferring Bv Elaboracion de degarelix
EP3250191B1 (fr) 2015-01-29 2024-01-17 Novo Nordisk A/S Comprimés contenant un agoniste de glp-1 et revêtement gastro-résistant
WO2017103275A1 (fr) * 2015-12-17 2017-06-22 Fresenius Kabi Anti-Infectives S.R.L Procédé de fabrication de dégarélix et de ses intermédiaires
CN107778355B (zh) * 2016-08-25 2021-04-20 成都圣诺生物制药有限公司 一种合成西曲瑞克的方法
WO2019110688A1 (fr) 2017-12-05 2019-06-13 Ferring B.V. Composition comprenant du dégarélix pour une utilisation dans le traitement du cancer du sein
CN111943960B (zh) 2019-07-29 2022-02-15 广东东阳光药业有限公司 取代的嘧啶二酮类化合物及其用途
US11332495B2 (en) 2019-09-21 2022-05-17 RK Pharma Solutions LLC Process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix
CN114456236A (zh) * 2020-11-09 2022-05-10 深圳市健翔生物制药有限公司 一种地加瑞克乙酰化杂质的制备方法
WO2023072284A1 (fr) 2021-11-01 2023-05-04 山东绿叶制药有限公司 Antagoniste de l'hormone de libération de la gonadotropine, son procédé de préparation et son utilisation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4547370A (en) * 1983-11-29 1985-10-15 The Salk Institute For Biological Studies GnRH Antagonists
US4508921A (en) * 1984-06-28 1985-04-02 Merck & Co., Inc. Process for preparation of alpha-alkyl amino acids
US4866160A (en) * 1985-04-09 1989-09-12 The Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US5073624A (en) * 1985-04-09 1991-12-17 Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
US4935491A (en) * 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
US5171835A (en) * 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
US5296468A (en) * 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
DE593491T1 (de) * 1991-04-25 1994-11-17 Romano S.-Cergue Deghenghi LHRH-Antagonisten.
CA2136079A1 (fr) * 1992-12-18 1994-07-07 Fortuna Haviv Antagonistes de lhrh presentant des residus aminoacyle modifies en position 5 et 6
IL108509A0 (en) * 1993-02-22 1994-05-30 Salk Inst For Biological Studi GnRH antagonist peptides
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists

Also Published As

Publication number Publication date
RU2199549C2 (ru) 2003-02-27
JP4249806B2 (ja) 2009-04-08
SK139699A3 (en) 2000-11-07
IL132303A0 (en) 2001-03-19
KR20010006233A (ko) 2001-01-26
CY1108063T1 (el) 2012-01-25
HK1025104A1 (en) 2000-11-03
FR09C0028I2 (fr) 2010-06-11
EE03974B1 (et) 2003-02-17
DE122009000033I1 (de) 2009-09-17
CN1230442C (zh) 2005-12-07
JP2005120101A (ja) 2005-05-12
US5925730A (en) 1999-07-20
DE122009000033I2 (de) 2011-07-21
HRP980197A2 (en) 1999-02-28
NO994906L (no) 1999-12-13
EE9900479A (et) 2000-06-15
PT1003774E (pt) 2006-05-31
KR100519421B1 (ko) 2005-10-06
EP1003774B1 (fr) 2006-03-08
NO994906D0 (no) 1999-10-08
AR011217A1 (es) 2000-08-02
BR9808523B1 (pt) 2010-02-09
ZA983062B (en) 1998-10-20
HUP0002704A2 (hu) 2000-12-28
MY114811A (en) 2003-01-31
UA58547C2 (uk) 2003-08-15
NL300395I2 (nl) 2010-01-04
NO2009016I2 (no) 2014-08-25
FR09C0028I1 (fr) 2009-09-25
BR9808523A (pt) 2000-05-23
TW505658B (en) 2002-10-11
JP2001523229A (ja) 2001-11-20
CA2286190A1 (fr) 1998-10-22
CY2009008I1 (el) 2012-01-25
HU224836B1 (en) 2006-03-28
AU728642B2 (en) 2001-01-11
NL300395I1 (nl) 2009-09-01
CZ358699A3 (cs) 2000-06-14
PL194509B1 (pl) 2007-06-29
JP3645255B1 (ja) 2005-05-11
UY24958A1 (es) 2001-03-16
DE69833751D1 (de) 2006-05-04
PL336213A1 (en) 2000-06-05
SI1003774T1 (sl) 2006-08-31
EP1003774A1 (fr) 2000-05-31
CY2009008I2 (el) 2012-01-25
NO2009016I1 (no) 2009-08-10
ATE319736T1 (de) 2006-03-15
CZ299097B6 (cs) 2008-04-23
NO324991B1 (no) 2008-01-14
AU6969898A (en) 1998-11-11
HRP980197B1 (en) 2002-08-31
HUP0002704A3 (en) 2003-08-28
WO1998046634A1 (fr) 1998-10-22
NZ500142A (en) 2001-10-26
CN1259959A (zh) 2000-07-12
TR199902956T2 (xx) 2000-08-21
CA2286190C (fr) 2007-01-09
DE69833751T2 (de) 2006-11-09
US6214798B1 (en) 2001-04-10
ES2260833T3 (es) 2006-11-01
DK1003774T3 (da) 2006-07-03
SK285381B6 (sk) 2006-12-07

Similar Documents

Publication Publication Date Title
LU91585I2 (fr) Degarelix, éventuellement un sel pharmaceutiquement acceptable, tel que l'acétate (FIRMAGON)
LU92699I2 (fr) Bazédoxifène, éventuellement sous la forme d'un sel pharmaceutiquement, acceptable tel que le sel d'acétate, et d'estrogènes conjugués
IL149005A0 (en) Hexahydrofuro-2', 3-bifuran-3-yl-n-{3'(1, 3-benzodioxol-5-ylsulfonyl) (isobutyl) amino-1-benzyl-2-hydroxypropyl} carbamate as restroviral protease inhibitor
IT1303740B1 (it) Piedistallo ad assorbimento d'urto per sedie.
EE9800298A (et) Farmatseutiliselt kasulikud ühendid
AU6088200A (en) Novel vasodilator cannabinoid analogs
IL125281A0 (en) Novel fungicidal composition comprising a 2-imidazolin-5-one
ITTO910894A0 (it) "un procedimento per preparare dipeptidi".
ZA967359B (en) Substituted benzothiazoles as crop protection agents.
IT1268094B1 (it) Struttura d'arresto di un cavalletto per un motoveicolo a due o tre ruote.
KR950700297A (ko) 5-HT3-수용체 길항제로서의 2,6-메타노-2H-퀴놀리진 유도체(2,6-Methano-2H-quinolizin derivative as 5-HT3-receptor antagonist)
NZ320449A (en) Dunnione as a fungicidal composition
FR2685212B1 (fr) Un systeme de protection des espaces boises contre l'incendie.
IT1299308B1 (it) Cavalletto per un motociclo.
IT1304182B1 (it) Struttura portante per un filatoio.
ITMI930017A0 (it) Composizione polimerizzabile per l'impreganzione di un supporto tessile, avente elevate caratteristiche tixotropiche
FR2735103B1 (fr) Support d'elements d'echafaudages.
KR920014295U (ko) 음성, 영상잭 보호커버
AP9901498A0 (en) Novel fungicidal composition comprising a 2-imidazolin-5-one
SE9001466D0 (sv) Stoeldskydd, saerskilt foer skor
ITMI960749V0 (it) Struttura portante per un'amaca
ITPG930006V0 (it) Supporto polifunzionale per operazioni di stirerie.
IT240105Y1 (it) Portabebe' orizzontale a tracolla.
IT240679Y1 (it) Spaziatore per la somministrazione di aerosol pre-dosato a volumevariabile
IT232859Y1 (it) puntale a vite di sostegno per ombrelloni.